enterprisetherapeutics.comCrawled Oct 27, 2026
A real-time visualization shows beating cilia inside a human bronchosphere, a 3D-cultured airway model. Ciliated cells lining the bronchosphere propel mucus, while goblet cells produce it, replicating airway function.
A screen of microbial products using a 3D human airway epithelium model identified flagellin (FLG) as a potential regulator of mucociliary structure and function. FLG, a TLR5-agonist, is a key protein in bacterial flagella, including those of *Pseudomonas aeruginosa*.
TMEM16A is a calcium-activated chloride channel and key regulator of anion secretion in human airway epithelium. Enhancing anion secretion improves mucus clearance and reduces exacerbations in cystic fibrosis patients, making TMEM16A a target for next-generation mucokinetics.
Enterprise Therapeutics has a pipeline of low-molecular-weight compounds, including ETD001, which targets the ENaC ion channel in airway epithelium. ETD001 completed a Phase 2 clinical trial.
The TLR5-agonist flagellin (FLG) is the key protein component of bacterial flagella, expressed by organisms including *Pseudomonas aeruginosa*. Its proinflammatory activity is documented in leukocytes, though effects on airway epithelial function remain unclear.
The hydration status of mucus in cystic fibrosis airways affects its clearance and influences plug formation, airflow restriction, and chronic microbial colonization. Strategies like CFTR repair, ENaC blockers, and TMEM16A potentiators aim to improve mucosal hydration.
Amit Munshi served as President and CEO of Arena Pharmaceuticals Inc. from 2016, leading its turnaround.
John Ford co-founded Xention (CSO), Ario Pharma (CEO), and Metrion Biosciences (co-owner). At Xention, he led the Kv1.5 ion channel atrial fibrillation project, later partnered with Servier. He also served as COO at Dezima, where Obicetrapib for dyslipidemia reached Phase 2b (published in *The Lancet*), before selling to Amgen.
Enterprise Therapeutics develops novel therapies for respiratory diseases, backed by venture capital investors. The company operates in the UK, with offices at the University of Sussex Innovation Centre and in Blackfriars, London.
In multiple pulmonary diseases including cystic fibrosis and chronic bronchitis the process of MCC is defective. This leads to lack of clearance of viruses, bacteria and pollutants resulting in lung infections which can irreversibly damage the lung.
More than 700 million people globally suffer from a respiratory disease
